title: Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy.
abstract: OBJECTIVE
  To evaluate the possible association between protease inhibitor (PI) and premature birth and low birth-weight in HIV-infected pregnancies.
  
  
  METHODS
  Data were collected retrospectively for maternal and pregnancy characteristics, antiretroviral medication, lowest CD4 count and highest viral load during pregnancy, and pregnancy outcomes. χ(2) Analysis, Student's t-test, and multiple logistic regression analysis were performed.
  
  
  RESULTS
  Data from 161 HIV-infected women who delivered singleton gestation were analyzed. Fifty-three received an antepartum regimen with PI, 84 received a regimen without PI, and six did not receive antepartum treatment. The mean estimated gestational age (EGA)± SD at delivery was 37.7 ± 3.2 weeks. The premature birth rate was 18.4%. No difference was detected between women receiving the antiretroviral regimen including PI and those on the regimen without PI or on no antepartum medication with regard to: EGA ± SD at delivery (37.7 ± 3.2 vs. 37.6 ± 3.1 weeks, respectively, P=0.87), rate of premature birth (14% vs. 20.6%, respectively, P=0.32) and low birth-weight (12.5% vs. 20.2%, respectively, P=0.25). In multiple logistic regression analysis, PI was not associated with premature birth or low birth-weight.
  
  
  CONCLUSIONS
  Women receiving antiretroviral therapy with PI have a similar rate of premature birth and low birth-weight as women receiving antiretroviral therapy without PI or on no medication.
authors: Department of Obstetrics and Gynecology, Tulane Health Sciences Center, Tulane University School of Medicine, New Orleans, LA 70112, USA. cdola@tulane.edu
authors: Chi P
authors: CP
authors: Dola
authors: Rubina
authors: R
authors: Khan
authors: Nathaniel
authors: N
authors: DeNicola
authors: Mahin
authors: M
authors: Amirgholami
authors: Tara
authors: T
authors: Benjamin
authors: Azad
authors: A
authors: Bhuiyan
authors: Sherri
authors: S
authors: Longo
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001724:Birth Weight / Q000187:drug effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D047928:Premature Birth / Q000139:chemically induced*; D011480:Protease Inhibitors / Q000009:adverse effects*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D011480:Protease Inhibitors